Zev A Wainberg - JoVE Visualize

Showing results (91-100 of 132) with videos related to

Pageof 14

Sort By:

JAMA Oncology|October 14, 2016

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical TrialMichael P Chu, J Randolph Hecht, Dennis Slamon, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerChristophe Massard, Michael S Gordon, Sunil Sharma, et al.

Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 27, 2019

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyYung-Jue Bang, Yoon-Koo Kang, Daniel V Catenacci, et al.

Investigational New Drugs|September 10, 2020

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.

The New England Journal of Medicine|June 1, 2026

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.

Lancet (London, England)|September 14, 2023

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trialZev A Wainberg, Davide Melisi, Teresa Macarulla, et al.

British Journal of Cancer|November 6, 2022

A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancerGiuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021

Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.

Nature Medicine|January 9, 2024

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trialShubham Pant, Zev A Wainberg, Colin D Weekes, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2020

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100Markus Moehler, Mikhail Dvorkin, Narikazu Boku, et al.

Pageof 14

Showing results (91-100 of 132) with videos related to

Sort By:

Pageof 14

JAMA Oncology|October 14, 2016

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical TrialMichael P Chu, J Randolph Hecht, Dennis Slamon, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerChristophe Massard, Michael S Gordon, Sunil Sharma, et al.

Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 27, 2019

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyYung-Jue Bang, Yoon-Koo Kang, Daniel V Catenacci, et al.

Investigational New Drugs|September 10, 2020

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.

The New England Journal of Medicine|June 1, 2026

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.

Lancet (London, England)|September 14, 2023

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trialZev A Wainberg, Davide Melisi, Teresa Macarulla, et al.

British Journal of Cancer|November 6, 2022

A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancerGiuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021

Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.

Nature Medicine|January 9, 2024

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trialShubham Pant, Zev A Wainberg, Colin D Weekes, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2020

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100Markus Moehler, Mikhail Dvorkin, Narikazu Boku, et al.

Pageof 14